| Project/Area Number |
18K16825
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56040:Obstetrics and gynecology-related
|
|---|
| Research Institution | National Center for Child Health and Development |
|---|
Principal Investigator |
Sasaki Aiko 国立研究開発法人国立成育医療研究センター, 周産期センター, 医師 (60560711)
|
|---|
| Project Period (FY) |
2018-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 同種免疫性疾患 / 母体免疫機能 / NK細胞 / 幼若化試験 / 新生児ヘモクロマトーシス / 血液型不適合 / 母体免疫細胞機能 / NK活性 / 胆汁酸 / Rh不適合 / 血液型不適合妊娠 / 母体免疫 / 母体免疫細胞機能解析 / 胆汁酸分析 / 母体免疫細胞活性 / 母体免疫細胞 / 免疫抑制 |
|---|
| Outline of Final Research Achievements |
Fetal-maternal alloimmune impairment diseases usually are treated by immune suppressive therapy such as IVIG infusion and prednisolone, however, there is no clinical markers to indicate the effectiveness of these therapy during pregnancy.
In this study, in order to know the normal temporal change in pregnancy and the difference in pregnancy with alloimmune disease, we examined three times of maternal immune function during each pregnancy in control group, Rh incompatibility group and neonatal hemochromatosis- gestational alloimmune liver disease (NH-GALD) group. Finally, we recruited 17 cases of control group, 20 cases of Rh incompatibility group and 6 cases of NH-GALD group. From now, we will analyze all the data to declare the difference in each group to find the clinical markers of good course pregnancy.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究により、同種免疫不適合妊娠の病態を反映する免疫学的バイオマーカーを絞り込み、候補と目安の数値を明らかにすることで、その推移をもとに、妊娠中でも免疫抑制治療の効果を推定でき、適切な治療を可能にするためのマーカーとして臨床応用へとつなげることが期待される。
|
